Avoro Capital Advisors LLC
Q3 2020 13F-HR Holdings
Net value change ($000)
+1,980,411
(39.2%)
New positions
9
Sold out positions
7
Turnover %
4.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IMMUNOMEDICS INC | 1,301,738 | 139.9% |
| Horizon Therapeutics Public Ltd Co | 260,772 | 78.2% |
| Mirati Therapeutics, Inc. | 231,735 | 47.3% |
| ARENA PHARMACEUTICALS INC | 172,046 | 287.7% |
| MyoKardia, Inc. | 75,336 | 41.5% |
| MDGL | 66,032 | 166.6% |
| PMVP | 57,578 | NEW |
| KURA | 57,493 | 335.9% |
| CymaBay Therapeutics, Inc. | 56,249 | 307.0% |
| XLRN | 52,835 | 53.3% |
Top Reduces (Value $000, Stocks/ETFs)
| BMRN | -95,039 | -41.7% |
| ADVM | -75,975 | -48.0% |
| ALLO | -48,326 | -100.0% |
| ZOGENIX, INC. | -45,084 | -74.2% |
| KPTI | -44,980 | -33.9% |
| CONSTELLATION PHARMACEUTICALS INC | -33,588 | -27.9% |
| SRPT | -33,350 | -12.4% |
| AUPH | -27,138 | -100.0% |
| Mersana Therapeutics, Inc. | -25,484 | -16.8% |
| Deciphera Pharmaceuticals, Inc. | -17,713 | -15.9% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|